Michelle Moorhouse

Michelle Moorhouse

Auto-generated profile, based on publicly available information

Michelle Moorhouse

Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
WVWillem D.F. Venter
Willem D.F. Venter
MMMichelle Moorhouse
Michelle Moorhouse
SSSimiso Sokhela
Simiso Sokhela
LFLee Fairlie
Lee Fairlie
NMNkuli Mashabane
Nkuli Mashabane
AHAndrew Hill
Andrew Hill
Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries.

31 January 2017 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
GMGraeme Meintjes
Graeme Meintjes
MMMichelle A. Moorhouse
Michelle A. Moorhouse
SCSergio Carmona
Sergio Carmona
NDNatasha Davies
Natasha Davies
SDSipho Dlamini
Sipho Dlamini
FVFrancois Venter
Francois Venter
These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in 2015. Since the release of the previous guidelines, the scale-up of antiretroviral therapy (ART) in southern Africa has continued. New antiretroviral drugs have become available with improved efficacy, safety and robustness. The guidelines are intended for countries in the southern African region, which vary between lower and middle income.

1 February 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
LHLucas E Hermans
Lucas E Hermans
MMMichelle Moorhouse
Michelle Moorhouse
SCSergio Carmona
Sergio Carmona
DGDiederick E Grobbee
Diederick E Grobbee
LHL Marije Hofstra
L Marije Hofstra
AWannemarie M.J. wensing
annemarie M.J. wensing

21 November 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
RERobyn Eakle
Robyn Eakle
GGGabriela B. Gomez
Gabriela B. Gomez
NNNiven Naicker
Niven Naicker
RBRutendo Bothma
Rutendo Bothma
JMJudie Mbogua
Judie Mbogua
OTon behalf of the TAPS Demonstration Project Team
on behalf of the TAPS Demonstration Project Team
Operational research is required to design delivery of pre-exposure prophylaxis (PrEP) and early antiretroviral treatment (ART). This paper presents the primary analysis of programmatic data, as well as demographic, behavioural, and clinical data, from the TAPS Demonstration Project, which offered both interventions to female sex workers (FSWs) at 2 urban clinic sites in South Africa. The TAPS study was conducted between 30 March 2015 and 30 June 2017, with the enrolment period ending on 31 July 2016. TAPS was a prospective observational cohort study with 2 groups receiving interventions delivered in existing service settings: (1) PrEP as part of combination prevention for HIV-negative FSWs and (2) early ART for HIV-positive FSWs. The main outcome was programme retention at 12 months of follow-up. Of the 947 FSWs initially seen in clinic, 692 were HIV tested. HIV prevalence was 49%. Among those returning to clinic after HIV testing and clinical screening, 93% of the women who were HIV-negative were confirmed as clinically eligible for PrEP (n = 224/241), and 41% (n = 110/270) of the women who were HIV-positive had CD4 counts within National Department of Health ART initiation guidelines at assessment. Of the remaining women who were HIV-positive, 93% were eligible for early ART (n = 148/160). From those eligible, 98% (n = 219/224) and 94% (n = 139/148) took up PrEP and early ART, respectively. At baseline, a substantial fraction of women had a steady partner, worked in brothels, and were born in Zimbabwe. Of those enrolled, 22% on PrEP (n = 49/219) and 60% on early ART (n = 83/139) were seen at 12 months; we observed high rates of loss to follow-up: 71% (n = 156/219) and 30% (n = 42/139) in the PrEP and early ART groups, respectively. Little change over time was reported in consistent condom use or the number of sexual partners in the last 7 days, with high levels of consistent condom use with clients and low use with steady partners in both study groups. There were no seroconversions on PrEP and 7 virological failures on early ART among women remaining in the study. Reported adherence to PrEP varied over time between 70% and 85%, whereas over 90% of participants reported taking pills daily while on early ART. Data on provider-side costs were also collected and analysed. The total cost of service delivery was approximately US$126 for PrEP and US$406 for early ART per person-year. The main limitations of this study include the lack of a control group, which was not included due to ethical considerations; clinical study requirements imposed when PrEP was not approved through the regulatory system, which could have affected uptake; and the timing of the implementation of a national sex worker HIV programme, which could have also affected uptake and retention. PrEP and early ART services can be implemented within FSW routine services in high prevalence, urban settings. We observed good uptake for both PrEP and early ART; however, retention rates for PrEP were low. Retention rates for early ART were similar to retention rates for the current standard of care. While the cost of the interventions was higher than previously published, there is potential for cost reduction at scale. The TAPS Demonstration Project results provided the basis for the first government PrEP and early ART guidelines and the rollout of the national sex worker HIV programme in South Africa.

1 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMark J. Siedner
Mark J. Siedner
MMMichelle A. Moorhouse
Michelle A. Moorhouse
BSBryony Simmons
Bryony Simmons
TOTulio De Oliveira
Tulio De Oliveira
RLRichard Lessells
Richard Lessells
RGRavindra Gupta
Ravindra Gupta
Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of second generation integrase inhibitors. We sequenced pretreatment plasma specimens from the ADVANCE trial (NCT03122262). Our primary outcome was 96-week virologic success, defined as a sustained viral load <1000 copies/mL from 12 weeks onwards, <200 copies/mL from 24 weeks onwards, and <50 copies/mL after 48 weeks. Here we report how this outcome was impacted by PDR, defined by the World Health Organization (WHO) mutation list. Of 1053 trial participants, 874 (83%) have successful sequencing, including 289 (33%) randomized to EFV-based therapy and 585 (67%) randomized to DTG-based therapy. Fourteen percent (122/874) have ≥1 WHO-defined mutation, of which 98% (120/122) are NNRTI mutations. Rates of virologic suppression are lower in the total cohort among those with PDR 65% (73/112) compared to those without PDR (85% [605/713], P < 0.001), and for those on EFV-based treatment (60% [12/20] vs 86% [214/248], P = 0.002) and for those on DTG-based treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen 0.49). Results are similar in multivariable models adjusted for clinical characteristics and adherence. NNRTI resistance prior to treatment is associated with long-term failure of integrase inhibitor-containing first-line regimens, and portends high rates of first-line failure in sub Saharan Africa.

16 September 2020 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
JNJeremy Nel
Jeremy Nel
SDSipho Dlamini
Sipho Dlamini
GMGraeme Meintjes
Graeme Meintjes
RBRosie Burton
Rosie Burton
JBJohn M. Black
John M. Black
JWJoana F. Woods
Joana F. Woods
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.